Jump to Header Jump to Main Content Jump to Footer

A Screening Study for Neoepitope-Specific T-Cells in Pts w/ Locally Adv or Met Solid Tumors

Daniela Bota


A Study On:

  • Cancer - Oncologic

Status:

  • Open

Eligibility

Inclusion Criteria:
- Histologically or cytologically documented incurable or metastatic solid tumors of the following types: melanoma, urothelial cancer, ovarian cancer, colorectal cancer, breast cancer (HR+), or prostate cancer.
- Adequate hematologic and end organ function
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1
- Note: There are additional inclusion criteria. The study center will determine if you meet all of the criteria.

Exclusion Criteria:
- More than two systemic chemotherapy regimens for advanced disease
- Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and/or inherited liver disease
- Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases
- Uncontrolled or symptomatic hypercalcemia
- Prior allogeneic stem cell transplant or solid organ transplant
- Prior chimeric antigen receptor therapy or other genetically modified T cell therapy
- Active HIV, Hepatitis B, or Hepatitis C infection
- History or risk of autoimmune disease
- Note: There are additional inclusion criteria. The study center will determine if you meet all of the criteria.

Interested in joining this trial?

Official Title

A Screening Study for Neoepitope-Specific T-Cells in Patients with Locally Advanced or Metastatic Solid Tumors

Get in touch with our study team